Abstract
Poziotinib is a potent tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) exon 20 mutations. The ZENITH20 global registrational study has demonstrated efficacy of poziotinib in previously treated patients with non-small cell lung cancer (NSCLC). Here, we present data from a phase 1 portion of the open-label study to determine the recommended dose (RD) and assess tolerability, safety, and efficacy of poziotinib in Japanese patients with NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
